First National Bank of Omaha Purchases Shares of 40,836 Amgen Inc. $AMGN

First National Bank of Omaha purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 40,836 shares of the medical research company’s stock, valued at approximately $11,524,000.

A number of other large investors have also recently made changes to their positions in AMGN. TAGStone Capital Inc. increased its position in Amgen by 0.8% in the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock worth $1,157,000 after buying an additional 32 shares during the last quarter. BBR Partners LLC grew its stake in shares of Amgen by 0.5% during the 3rd quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock worth $2,008,000 after acquiring an additional 32 shares during the period. Wealth Quarterback LLC increased its holdings in Amgen by 1.6% in the 3rd quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock worth $624,000 after acquiring an additional 34 shares during the last quarter. DDFG Inc raised its stake in Amgen by 1.1% in the 3rd quarter. DDFG Inc now owns 3,014 shares of the medical research company’s stock valued at $850,000 after acquiring an additional 34 shares during the period. Finally, Crown Wealth Group LLC lifted its holdings in Amgen by 4.0% during the third quarter. Crown Wealth Group LLC now owns 910 shares of the medical research company’s stock valued at $257,000 after purchasing an additional 35 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Mizuho lifted their price target on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. UBS Group raised their target price on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Leerink Partners upped their price target on Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Wall Street Zen cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 7th. Finally, Oppenheimer set a $400.00 target price on shares of Amgen and gave the stock an “outperform” rating in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $354.04.

Amgen Trading Up 1.1%

Shares of AMGN opened at $373.36 on Wednesday. The stock has a market capitalization of $201.05 billion, a P/E ratio of 26.24, a PEG ratio of 3.78 and a beta of 0.46. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $385.12. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a fifty day simple moving average of $339.62 and a two-hundred day simple moving average of $314.83.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. Amgen’s payout ratio is presently 70.84%.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This represents a 30.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.76% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.